PINOVA THERAPEUTICS
LIVE

Serial Number

97135396

Owner

Pocket Naloxone Corp.

Attorney

Spencer Wolff Esquire

First Use Date

Jun 3, 2025

Filing Date

Nov 19, 2021

Add to watchlist:

No watchlists yet
View on USPTO

PINOVA THERAPEUTICS Trademark

Serial Number: 97135396 • Registration: 8285284

PINOVA THERAPEUTICS is a trademark filed by Pocket Naloxone Corp. on November 19, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Pocket Naloxone Corp.

4701 Sangamore Road, #100N
Bethesda, MD 20816

Entity Type: 03

Trademark Details

Filing Date

November 19, 2021

Registration Date

June 2, 2026

First Use Anywhere

June 3, 2025

First Use in Commerce

June 3, 2025

Published for Opposition

July 18, 2023

Goods & Services

medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty

pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty

scientific research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 2, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 2, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 11, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 11, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 11, 2026 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 6, 2026 AITU
USE AMENDMENT FILED
Oct 17, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Oct 17, 2025 EISU
SOU EXTENSION RECEIVED WITH TEAS PETITION
Oct 17, 2025 TPEX
NOTICE OF REVIVAL - E-MAILED
Oct 17, 2025 NREV
PETITION TO REVIVE-GRANTED
Oct 17, 2025 PETG
TEAS PETITION TO REVIVE RECEIVED
Oct 17, 2025 PROA
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 13, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 13, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 20, 2025 EXRA
SOU EXTENSION 3 GRANTED
Feb 19, 2025 EX3G
SOU EXTENSION 3 FILED
Feb 19, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 21, 2024 EXRA
SOU EXTENSION 2 GRANTED
Aug 21, 2024 EX2G
SOU EXTENSION 2 FILED
Aug 21, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 21, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 5, 2024 EXRA
SOU EXTENSION 1 GRANTED
Mar 2, 2024 EX1G
SOU EXTENSION 1 FILED
Mar 2, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 2, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 12, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 18, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 28, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 8, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 11, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 11, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 11, 2023 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 14, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 14, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 14, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 14, 2023 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 11, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 11, 2023 GNRT
NON-FINAL ACTION WRITTEN
Apr 11, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 2, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 28, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 28, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 31, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 31, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 31, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 30, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 24, 2021 NWOS
NEW APPLICATION ENTERED
Nov 23, 2021 NWAP